13.00
2.48%
-0.33
アフターアワーズ:
13.00
前日終値:
$13.33
開ける:
$13.14
24時間の取引高:
977.46K
Relative Volume:
1.47
時価総額:
$158.33M
収益:
$1.54M
当期純損益:
$-38.70M
株価収益率:
-1.1818
EPS:
-11
ネットキャッシュフロー:
$-36.86M
1週間 パフォーマンス:
-13.79%
1か月 パフォーマンス:
-19.15%
6か月 パフォーマンス:
-69.53%
1年 パフォーマンス:
+150.00%
Corbus Pharmaceuticals Holdings Inc Stock (CRBP) Company Profile
名前
Corbus Pharmaceuticals Holdings Inc
セクター
電話
617-963-0103
住所
500 RIVER RIDGE DRIVE, NORWOOD, MA
CRBP を他の銘柄と比較する
株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
---|---|---|---|---|---|---|
CRBP
Corbus Pharmaceuticals Holdings Inc
|
13.00 | 158.33M | 1.54M | -38.70M | -36.86M | -4.67 |
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Corbus Pharmaceuticals Holdings Inc Stock (CRBP) Upgrades & Downgrades
日付 | アクション | アナリスト | 評価の変更 |
---|---|---|---|
2024-12-02 | 開始されました | Piper Sandler | Overweight |
2024-07-30 | 開始されました | Wedbush | Outperform |
2024-07-22 | 再開されました | H.C. Wainwright | Buy |
2024-06-26 | 開始されました | B. Riley Securities | Buy |
2024-06-03 | 繰り返されました | Oppenheimer | Outperform |
2024-05-13 | 開始されました | RBC Capital Mkts | Outperform |
2024-03-06 | アップグレード | Jefferies | Hold → Buy |
2020-09-08 | ダウングレード | BTIG Research | Buy → Neutral |
2020-09-08 | ダウングレード | Jefferies | Buy → Hold |
2020-09-08 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
2020-09-08 | ダウングレード | ROTH Capital | Buy → Neutral |
2020-07-07 | 開始されました | ROTH Capital | Buy |
2020-06-17 | 開始されました | BTIG Research | Buy |
2020-03-26 | 開始されました | Nomura | Buy |
2019-04-05 | 開始されました | Jefferies | Buy |
2019-03-20 | 開始されました | Oppenheimer | Outperform |
2019-01-11 | 繰り返されました | Cantor Fitzgerald | Overweight |
2018-12-26 | 開始されました | H.C. Wainwright | Buy |
2018-12-07 | 開始されました | RBC Capital Mkts | Outperform |
2018-10-24 | 開始されました | B. Riley FBR | Buy |
2018-01-19 | 開始されました | Raymond James | Outperform |
2017-12-14 | 繰り返されました | Cantor Fitzgerald | Overweight |
2017-11-08 | 繰り返されました | Noble Financial | Buy |
2017-09-29 | 再開されました | Noble Financial | Buy |
2017-03-30 | 繰り返されました | Cantor Fitzgerald | Overweight |
2016-11-15 | 繰り返されました | JMP Securities | Mkt Outperform |
2016-11-11 | 繰り返されました | Noble Financial | Buy |
すべてを表示
Corbus Pharmaceuticals Holdings Inc (CRBP) 最新ニュース
Corbus Pharmaceuticals Holdings Inc. stock underperforms Thursday when compared to competitors despite daily gains - MarketWatch
Analysts Set Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) PT at $62.00 - MarketBeat
(CRBP) Investment Report - Stock Traders Daily
Corbus Pharmaceuticals Holdings Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
Corbus Pharmaceuticals Holdings Inc. stock underperforms Tuesday when compared to competitors despite daily gains - MarketWatch
Mizuho remains bullish on Corbus stock, sees encouraging outlook for Nectin-4 ADC - Investing.com Canada
Charles Schwab Investment Management Inc. Buys 64,800 Shares of Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) - MarketBeat
Charles Schwab Investment Management Inc. Boosts Stock Position in Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) - Defense World
Corbus Pharmaceuticals Holdings Inc. stock underperforms Monday when compared to competitors - MarketWatch
Corbus Pharmaceuticals' SWOT analysis: stock's potential in cancer and obesity - Investing.com
Corbus Pharmaceuticals Holdings Inc. stock remains steady Friday, underperforms market - MarketWatch
Corbus Pharmaceuticals Holdings Inc. stock underperforms Thursday when compared to competitors - MarketWatch
Corbus Pharmaceuticals Holdings Inc. stock outperforms competitors on strong trading day - MarketWatch
Corbus begins phase 1 trial for advanced solid tumors By Investing.com - Investing.com South Africa
Corbus Pharmaceuticals Holdings Inc. stock outperforms competitors despite losses on the day - MarketWatch
Corbus begins phase 1 trial for advanced solid tumors - Investing.com
Corbus Pharmaceuticals Announces Dosing of First Patient in its First-In-Human Study of CRB-601 to Treat Patients with Advanced Solid Tumors - The Manila Times
Corbus Pharmaceuticals Announces Dosing of First Patient in - GlobeNewswire
Corbus Pharma Launches Phase 1 Trial for Novel Cancer Immunotherapy CRB-601 - StockTitan
2 'Strong Buy' Biotech Stocks With 120% or More Upside Potential - MSN
Eli Lilly and Company (LLY-N) QuotePress Release - The Globe and Mail
Trading (CRBP) With Integrated Risk Controls - Stock Traders Daily
Walleye Capital LLC Sells 113,428 Shares of Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) - MarketBeat
Why Is Corbus Pharmaceuticals Holdings, Inc. (CRBP) Among the Best Small-Cap Biotech Stocks With Massive Potential According to Hedge Funds? - Insider Monkey
FDA fast tracks Corbus drug for cervical cancer treatment By Investing.com - Investing.com Canada
Corbus Pharmaceuticals' CRB-701 Receives FDA Fast Track Designation for Metastatic Cervical Cancer Treatment - Marketscreener.com
Corbus Pharmaceuticals Holdings Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
Corbus Pharmaceuticals Holdings Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits - Quantisnow
Piper Sandler Initiates Coverage of Corbus Pharmaceuticals Holdings (CRBP) with Overweight Recommendation - MSN
HighVista Strategies LLC Acquires 36,499 Shares of Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) - MarketBeat
FDA fast tracks Corbus drug for cervical cancer treatment - Investing.com
FDA Grants Fast Track Designation to CRB-701 for the Treatment of Relapsed or Refractory Metastatic Cervical Cancer - GlobeNewswire
Corbus Pharma Secures FDA Fast Track Status for Cancer Drug CRB-701 - StockTitan
CRBP (Corbus Pharmaceuticals Holdings) Financial Strength : 8 (As of Sep. 2024) - GuruFocus.com
Corbus Pharmaceuticals stock rated Overweight, CRB-701 could drive solid tumor efficacy - Investing.com Canada
Corbus Pharmaceuticals Holdings Inc. stock rises Monday, still underperforms market - MarketWatch
Corbus, Viking initiated at overweight by Piper Sandler (NASDAQ:VKTX) - Seeking Alpha
CRBP (Corbus Pharmaceuticals Holdings) Enterprise Value : $61.43 Mil (As of Dec. 02, 2024) - GuruFocus.com
Victory Capital Management Inc. Boosts Holdings in Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) - Defense World
Acuta Capital Partners LLC Reduces Stock Holdings in Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) - MarketBeat
Corbus Pharmaceuticals Holdings Inc. stock rises Tuesday, still underperforms market - MarketWatch
Corbus Pharmaceuticals Holdings, Inc. (CRBP): An Oversold Healthcare Stock to Invest In Now - Insider Monkey
CRBP (Corbus Pharmaceuticals Holdings) Change In Working Ca - GuruFocus.com
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) Receives Average Rating of "Buy" from Analysts - MarketBeat
Corbus Pharmaceuticals to Present at the 7th Annual Evercore HealthCONx Conference - Investing.com Australia
CRBPCorbus Pharmaceuticals Holdings, Inc. Latest Stock News & Market Updates - StockTitan
Corbus Pharmaceuticals to Present at Evercore HealthCONx Conference in December | CRBP Stock News - StockTitan
Corbus Pharmaceuticals Holdings Inc (CRBP) 財務データ
収益
当期純利益
現金流量
EPS
大文字化:
|
ボリューム (24 時間):